Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 10/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL484644 | 0.89 | SIGMAR1 (0.56) | CYP2D6MEN1KMT2AUSP2CYP3A4 | |
| SCHEMBL14027000 | 0.85 | ALDH1A1 (0.64) | CYP2D6MEN1KMT2AUSP2CYP3A4 | |
| SCHEMBL8892977 | 0.82 | GAA (0.59) | CYP2D6MEN1KMT2AUSP2GAA | |
| SCHEMBL31230946 | 0.82 | CYP2D6 (0.61) | CYP2D6MEN1KMT2AUSP2GAA | |
| SCHEMBL3464617 | 0.82 | CYP2D6 (0.61) | CYP2D6MEN1KMT2AUSP2GAA | |
| SCHEMBL27798357 | 0.81 | SIGMAR1 (0.62) | CYP2D6MEN1KMT2AUSP2GAA | |
| SCHEMBL31230966 | 0.80 | CYP2D6 (0.59) | CYP2D6MEN1KMT2AUSP2GAA | |
| SCHEMBL5243003 | 0.78 | CYP2D6 (0.67) | CYP2D6MEN1KMT2AUSP2CYP3A4 | |
| SCHEMBL17444058 | 0.78 | DDB1 (0.45) | CYP2D6MEN1KMT2AUSP2GAA | |
| SCHEMBL31230967 | 0.77 | CYP2D6 (0.55) | CYP2D6MEN1KMT2AUSP2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092737-A1 | Benzopiperidine derivatives | EISAI CO., LTD. | 2004-05-13 | — | — | US | disclosed |
| US-6518423-B1 | These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and | EISAI CO., LTD. (JP) | 2003-02-11 | — | — | US | disclosed |
| EP-0934941-A1 | BENZOPIPERIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 1999-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092737-A1 | Benzopiperidine derivatives | HLA-DRB1, HRH1, HRH2 | CYP2D6 32/4885MEN1 4580/4885KMT2A 3395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.